Author: jessica

Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089

by on February 12, 2024

Redwood City, Calif., February 12, 2024 – Nuvig Therapeutics, Inc., (“Nuvig” or the “Company”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease. Nuvig also announced…

Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer

by on October 4, 2023

Physician and biopharmaceutical leadership executive with extensive experience in novel drug development, operations management, and team building Redwood City, Calif., October 4, 2023 – Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer. Dr. Glicklich has…

Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases

by on May 11, 2022

Redwood City, Calif., May 11, 2022 – Nuvig Therapeutics, Inc., announced today the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function. To support this mission, the company has closed a $47 million Series A financing, led by Novo Holdings A/S…